References
- Beaumont C, Young GC, Cavalier T, Young MA. (2014). Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches. Br J Clin Pharmacol 78:1185–200.
- Bhole V, de Vera M, Rahman MM, et al. (2010). Epidemiology of gout in women: fifty-two-year followup of a prospective cohort. Arthritis Rheum 62:1069–76.
- Boulton DW, Kasichayanula S, Keung CF, et al. (2012). Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol 75:763–8.
- Enayetallah AE, French RA, Thibodeau MS, Grant DF. (2004). Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 52:447–54.
- Fretland AJ, Omiecinski CJ. (2000). Epoxide hydrolases: biochemistry and molecular biology. Chem Biol Interact 129:41–59.
- Grayson PC, Kim SY, LaValley M, Choi HK. (2011). Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63:102–10.
- Gunic E, Galvin G. (2014). Manufacture of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid, U.S. patent 2013/049135.
- Heap G, Sosa MP. (2012). Gout chart audit. BioTrends Research Group and Decision Resources Group.
- Khanna D, Fitzgerald JD, Khanna PP, et al. (2012). American College of Rheumatology guidelines for management of gout, part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–46.
- Kitamura S, Kuwasako M, Ohta S, Tatsumi K. (1999). Reductive debromination of (alpha-bromoiso-valeryl)urea by intestinal bacteria. J Pharm Pharmacol 51:79–84.
- Lakehal F, Wendum D, Barbu V, et al. (1999). Phase I and phase II drug-metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium. Hepatology 30:1498–506.
- Lappin G, Shishikura Y, Jochemsen R, et al. (2010). Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 40:125–31.
- Mikuls TR, Farrar JT, Bilker WB, et al. (2005). Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 64:267–72.
- Nakagawa T, Hu H, Zharikov S, et al. (2006). A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290:F625–631.
- Nishimura M, Yaguti H, Yoshitsugu H, et al. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123:369–75.
- Richette P, Doherty M, Pascual E, et al. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29–42.
- Sarapa N, Hsyu P-H, Lappin G, Garner RC. (2005). The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol 45:1198–205.
- Smith DA, Obach RS. (2009). Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22:267–79.
- Zhu Y, Pandya BJ, Choi HK. (2011). Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 63:3136–3141.